These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10346284)

  • 21. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 21st century cures act: Opportunities and challenges.
    Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
    Schmidt K
    MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
    [No Abstract]   [Full Text] [Related]  

  • 24. Health technology adoption and the politics of governance in the UK.
    Milewa T
    Soc Sci Med; 2006 Dec; 63(12):3102-12. PubMed ID: 16982120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
    Harder Yv
    Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
    [No Abstract]   [Full Text] [Related]  

  • 27. [About science and politics].
    Erdmann E
    Dtsch Med Wochenschr; 2003 Apr; 128(15):789. PubMed ID: 12690571
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cannabis in medicine. Legal aspects].
    Wartensleben H
    Schmerz; 2004 Dec; 18 Suppl 2():S34-5. PubMed ID: 23570089
    [No Abstract]   [Full Text] [Related]  

  • 29. TRICARE; off-label uses of devices; partial list of examples of unproven drugs, devices, medical treatments or procedures. Final rule.
    Office of the Secretary, Department of Defense (DoD)
    Fed Regist; 2012 Jun; 77(124):38177-8. PubMed ID: 22737762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical technology and inequity in health care: the case of Korea.
    Yang BM
    Health Policy Plan; 1993 Dec; 8(4):385-93. PubMed ID: 10131034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Health technology assessment in the international context: where does Germany stand? For the "German Scientific Working Group Technology Assessment for Health care"].
    Bitzer EM; Busse R; Kohlmann T; Lühmann D; Perleth M
    Z Arztl Fortbild Qualitatssich; 1999 Jan; 93(1):33-8. PubMed ID: 10198976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'Fourth hurdle reviews', NICE, and database applications.
    Paul JE; Trueman P
    Pharmacoepidemiol Drug Saf; 2001; 10(5):429-38. PubMed ID: 11802589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 35. Evidence, appropriateness, and technology assessment in cardiology: a case study of computed tomography.
    Redberg RF
    Health Aff (Millwood); 2007; 26(1):86-95. PubMed ID: 17211017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technology coverage decisions by health care plans and considerations by medical directors.
    Steiner CA; Powe NR; Anderson GF; Das A
    Med Care; 1997 May; 35(5):472-89. PubMed ID: 9140336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assessment of benefit and efficiency of innovative medical devices].
    Perleth M; Lühmann D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):825-30. PubMed ID: 20700782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling for health care and other policy decisions: uses, roles, and validity.
    Weinstein MC; Toy EL; Sandberg EA; Neumann PJ; Evans JS; Kuntz KM; Graham JD; Hammitt JK
    Value Health; 2001; 4(5):348-61. PubMed ID: 11705125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
    Hailey D
    Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.